Indian journal of cancer最新文献

{"title":"Esophageal mixed or collision small cell-squamous cell carcinoma: Report of 6 cases and review of the literature.","authors":"Huajun Sun, Yanfen Shi, Dongni Liang, Juan Liu, Gang Xu, Xudan Yang","doi":"10.4103/ijc.IJC_173_21","DOIUrl":"10.4103/ijc.IJC_173_21","url":null,"abstract":"<p><strong>Background: </strong>Esophageal mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs) are now known as a neuroendocrine component mixed with a nonneuroendocrine component in a single neoplasm, one of which is in the form of mixed small cell-squamous cell carcinoma. Collision tumors have been excluded from the category of MiNENs, but difference between mixed and collision small cell-squamous cell carcinoma has never been reported.</p><p><strong>Methods: </strong>We collected six cases and reviewed 11 cases of mixed or collision small cell-squamous cell carcinoma (MCSSC); the data from 17 cases of MCSSC were analyzed to observe their clinicopathological features.</p><p><strong>Results: </strong>Most of the MCSSC patients were middle-aged and elderly, with more men than women, and most of the tumors occurred in the middle and lower esophagus. We found that in mixed cancers, the metastases were a mixture of squamous cell carcinoma and small cell carcinoma, whereas metastatic foci in collisional tumors showed simple cancer components; this phenomenon has never been reported before. Mixed cancers account for a higher proportion of small cell carcinomas, a higher pathological stage, and a worse prognosis than collisional cancers. PD-L1 (22C3) was negative in both squamous cell carcinoma and small cell carcinoma regions (<1%).</p><p><strong>Conclusions: </strong>Mixed and collisional small cell-squamous cell carcinomas are essentially distinct tumors. In the clinical diagnostic of MCSSC, the tumor should be clearly identified as mixed or collisional carcinoma to guide the clinical treatment and prognosis more accurately.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"759-765"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of ultrasound-guided percutaneous needle biopsy for diagnosis of peripheral pulmonary lesions: A retrospective cohort study.","authors":"Kehong Chen, Rui Chen, Ze Ning, Weifeng Xu, Chengyu Zhang, Hongyan Yu, Xuemei Ou, Qingxiong Zhang, Chengguo Li, Qiu Luo, Yongsheng Yang","doi":"10.4103/ijc.IJC_1216_20","DOIUrl":"10.4103/ijc.IJC_1216_20","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the diagnostic accuracy of ultrasound-guided (US-guided) percutaneous needle biopsy (PNB) and related influencing factors that could provide references for clinicians to improve the diagnostic accuracy of peripheral pulmonary lesions (PPLs).</p><p><strong>Methods: </strong>We retrospectively analyzed 318 consecutive cases with PPLs who underwent US-guided PNB successfully in Chongqing Red Cross Hospital, Fusheng Community Health Service Center, Maoershi Community Health Service Center, and Yuzui Community Health Service Center. We collected pathological results of ultrasound-guided biopsy, clinical final diagnosis, disease course records, and postoperative complications of these patients. According to whether the pathological diagnosis of biopsy of US-guided PNB was consistent with the final clinical diagnosis, it can be divided into true positive, false positive, true negative, and false negative to calculate diagnostic yield. The factors affecting the diagnostic accuracy were assessed between diagnosed cases (true positive and true negative) and non-diagnosed cases (false negative and uncertain) by the Chi-Square test.</p><p><strong>Results: </strong>Among the 318 patients, 292 cases had determinate pathological diagnosis through US-guided PNB and 26 cases were indeterminate. The diagnostic yield including diagnostic accuracy, sensitivity, specificity, positive-predictive value, and negative predictive value in 318 patients under US-guided PNB was 86.2%, 73.8%, 85.2%, 82.7%, and 77.3%, respectively. The total complication rate was 6.0%. After analyzing multiple factors during the biopsy process, we found that the size of lesion had a significant impact on the diagnostic accuracy of US-guided PNB.</p><p><strong>Conclusion: </strong>Ultrasound-guided percutaneous needle biopsy has a high success rate and diagnostic accuracy, which is an effective and accurate method for the diagnosis of peripheral lung diseases. The size of lesions can affect the diagnostic accuracy.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"703-709"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel oncoplastic technique for centrally located breast cancers: An experience from a Tertiary care center in North India.","authors":"Vikas Sharma, Sandhya Pandey, Gaurav Gupta, Ajeet Gandhi, Madhup Rastogi, Rohini Sethi, Sachan Beena","doi":"10.4103/ijc.IJC_1063_20","DOIUrl":"10.4103/ijc.IJC_1063_20","url":null,"abstract":"<p><strong>Context: </strong>Oncoplastic breast surgery is the current standard for treatment of early breast cancer, offering a balance between good cosmetic outcomes and limited risk of locoregional recurrence. Still, the best technique of reconstruction for centrally located breast cancer (CLBC) is not established because of cosmetic issues associated with NAC resection and difficulties associated with its reconstruction.</p><p><strong>Aims: </strong>This study aims to present here a novel technique of post-BCS breast reconstruction for CLBC by latissimus dorsi (LD) flap coupled with immediate NAC reconstruction using modified Skate Flap.</p><p><strong>Methods and material: </strong>A total of 9 patients underwent oncoplastic breast reconstruction using the described technique for CLBC at our center from July 2018 to March 2020. Postoperative analysis was done for surgical complications, pathological, oncological, and cosmetic outcomes. QOL outcome was assessed using body image scale (BIS) and compared with another group of 9 mastectomy patients operated in the same time period.</p><p><strong>Statistical analysis: </strong>The analysis was done using SPSS software. P value was calculated using the Independent t-test.</p><p><strong>Results: </strong>Mean BIS score was 4.44 (range 1-8) in BCS vs 20 (range 11-27) in the mastectomy group, signifying better QOL in the BCS group. The postoperative cosmetic results, as evaluated by the patients, were excellent in 7 of 9 patients (77.77%), good in 1 patient (11.11%), and fair in 1 (11.11%), with an overall mean of 4.11 equivalent to 82% satisfaction.</p><p><strong>Conclusions: </strong>Immediate reconstruction with LD flap and modified skate flap following resection of CLBC is a good technique for this difficult group of patients to be managed by BCS. Cosmetic results of this technique are satisfactory. Additionally, it avoids the need for a symmetrizing contralateral breast surgery as well as a second surgery on the ipsilateral breast.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"687-693"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term efficacy and safety of camrelizumab-based treatment in refractory or metastatic esophageal squamous cell carcinoma.","authors":"Yuan Yuan, Qingliang Meng, Xiaowu Li, Youwei Zhang, Sanyuan Sun","doi":"10.4103/ijc.IJC_1275_20","DOIUrl":"10.4103/ijc.IJC_1275_20","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the short-term efficacy and safety of camrelizumab in combination with apatinib in the treatment of refractory or metastatic esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of 30 patients with refractory or metastatic ESCC treated with camrelizumab in combination with apatinib at a single institution. The short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria. The safety was evaluated by the Common Terminology Criteria for Adverse Events criteria.</p><p><strong>Results: </strong>Among all the 30 patients, the overall response rate and disease control rate were 8/30 (27%) and 19/30 (63%), respectively. Complete response was achieved in 0/30 (0%), partial response in 8/30 (27%), stable disease in 11/30 (36%), and progressive disease in 11/30 (37%). The median progression-free survival was 3.7 (95% confidence interval: 2.48 - 3.88) months and the median overall survival was not reached.</p><p><strong>Conclusion: </strong>Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"710-713"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of obsessive-compulsive disorder in cancer patients: A case-control study.","authors":"Fatih İnci, Habibe İnci","doi":"10.4103/ijc.IJC_1413_20","DOIUrl":"10.4103/ijc.IJC_1413_20","url":null,"abstract":"<p><strong>Background: </strong>This study was aimed to investigate the frequency of obsessive-compulsive disorder, which is known to cause depression in cancer patients and may result in cancer treatment failure.</p><p><strong>Materials and methods: </strong>A total of 202 cancer patients and 322 healthy individuals were included in this cross-sectional, case-control study. Sociodemographic data form and Maudsley Obsessive-Compulsive Questionnaire (MOCQ) were administered to the participants. The cancer patients' current MOCQ scores and prediagnosis MOCQ scores, and the MOCQ scores of the control group were compared.</p><p><strong>Results: </strong>When the cancer patients and control groups were evaluated according to the MOCQ scales, the cancer patients' MOCQ-control, MOCQ-doubt, MOCQ-rumination, and MOCQ-total scores were found to be higher compared with the control group (P < 0.001, all). When the cancer patients' prediagnosis and postdiagnosis MOCQ scores were compared, it was found that their MOCQ-control, MOCQ-cleanliness, MOCQ-doubt, MOCQ-rumination, and MOCQ-total scores after cancer diagnosis were higher than those before cancer diagnosis (P < 0.001, all). In the cancer patients group, it was observed that the MOCQ scores were higher in those who were at the early stage (P = 0.008), women (P < 0.001), unmarried (P = 0.004), highly educated (P = 0.006), unemployed (P = 0.037), and living in a city center (P = 0.023). There was a positive correlation between the cancer stage and the MOCQ-slowness score (P = 0.043). According to the logistic regression analysis, being a woman, having a high education level, living in a city, and having early-stage cancer were found to be the independent predictive factors for the increased MOCQ scores in cancer patients.</p><p><strong>Conclusion: </strong>It was observed that the MOCQ scores were higher in the cancer patients compared with those in the control group, and the cancer patients' MOCQ scores increased after diagnosis. Having an early-stage cancer disease, being a woman, having a high education level, and living in a city center were the predictive factors for the increased MOCQ scores in cancer patients.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"741-748"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysmorphic plasma cells in multiple myeloma.","authors":"Priyadarshini Kumaraswamy Rajeswaran, Sakthisankari Shanmugasundaram, Prasanna N Kumar","doi":"10.4103/ijc.ijc_884_21","DOIUrl":"https://doi.org/10.4103/ijc.ijc_884_21","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"845-846"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of adaptive radiotherapy during concomitant chemoradiotherapy for limited-stage small-cell lung cancer.","authors":"Beyza Sirin Ozdemir, Ali A Yavuz","doi":"10.4103/ijc.IJC_578_20","DOIUrl":"10.4103/ijc.IJC_578_20","url":null,"abstract":"<p><strong>Background: </strong>Tumor shrinkage is frequently observed during conventionally fractionated chemoradiotherapy for limited-stage small-cell lung cancer (SCLC). The specific goals of this study are to evaluate the gross tumor volume (GTV) changes due to treatment-induced tumor reduction during the course of radiotherapy (RT) and to examine its potential use in adaptive radiotherapy (ART) for tumor dose escalation or normal tissue sparing in patients with SCLC.</p><p><strong>Materials and methods: </strong>A total of 10 patients with SCLC eligible for chemoradiotherapy underwent computed tomography (CT) scan after Fractions 13 and 23 (at nominal doses of 23.4 Gy and 41.4 Gy, respectively). The GTV was delineated on the repeat CT scans, and two treatment plans were generated with or without adaptation to tumor shrinkage during RT for each patient. Dosimetric and volumetric analyses were performed.</p><p><strong>Results: </strong>The average GTV reduction observed over 13 fractions was 58.5% (range: 13.2%-92.3%; P < 0.001) and over 23 fractions was 70% (range: 36.9%-84.5%; P < 0.001). Compared with the plan without adaptation, ART resulted in mean lung dose relative decreases of 8.7%, mean lung volume receiving ≥20 Gy relative decreases of 5%, mean lung volume receiving ≥5Gy relative decreases of 10%, mean medulla spinalis dose relative decreases of 21 cGy, mean esophagus volume receiving ≥50 Gy relative decreases of 19%, and mean heart volume receiving ≥42 Gy relative decreases of 13%. The benefits of ART were the greatest for tumor volumes ≥30 cm 3 and are directly dependent on GTV reduction during treatment.</p><p><strong>Conclusion: </strong>ART for SCLC achieved a significant benefit in terms of organ at risk (OAR) and dose escalation.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction of HPV vaccine in universal immunization programme of India: A step in the right direction for the elimination of cervical cancer.","authors":"Md Abu Bashar, Imran A Khan","doi":"10.4103/ijc.ijc_26_23","DOIUrl":"10.4103/ijc.ijc_26_23","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of quality of life in head and neck cancer patients visiting the Palliative Care outpatient department in a tertiary care oncology centre in India.","authors":"Abhity Gulia, Nishkarsh Gupta, Prateek Sharma, Vinod Kumar, Rajeev Kumar, Seema Mishra, Sushma Bhatnagar","doi":"10.4103/ijc.IJC_1247_20","DOIUrl":"10.4103/ijc.IJC_1247_20","url":null,"abstract":"<p><strong>Background: </strong>Patients with head and neck cancers (HNCs) are at an increased risk of developing functional symptoms associated with eating, speaking, and breathing along with symptoms caused by a fungating tumour (e.g., cosmetic change, malodor, and bleeding). These may substantially reduce their physical functioning and quality of life (QoL). This observational study aimed to find out the QoL in patients with HNC in a tertiary care oncology centre.</p><p><strong>Methods: </strong>A prospective observational study was conducted in adult patients diagnosed with HNC. The patients were divided depending upon their disease extent into early, advanced, and very advanced local disease. The physical, cognitive, emotional, financial and social domains were assessed using a validated Hindi version of the European Organisation for Research and Treatment of cancer (EORTC)- QoL 30 and EORTC H&N 35 at baseline and 3 months.</p><p><strong>Results: </strong>A total of 100 patients were assessed with a mean age of 49.3 ± 12.4 years. Most of the patients had carcinoma buccal mucosa (42%) followed by carcinoma tongue (17%). The patients experienced difficulties with physical functioning and deterioration in emotional functioning. Pain and fatigue were the major problematic symptoms especially in advanced disease patients resulting in poor QoL. There was a significant improvement in various domains of QoL at 3 months follow-up in those with advanced disease. The fatigue scores at baseline and follow-up showed a positive correlation with other symptoms.</p><p><strong>Conclusion: </strong>Patients with HNC have a high symptom burden that leads to poor QoL. Appropriate palliative care interventions help to decrease symptom burden and prevent deterioration of their QoL in patients with HNC.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer","authors":"Furong Liu, Yuehua Li, Dinghua Yang, Li Tang, Qian Yang, Majiao Jiang, Leilei Tian, Jingjing An","doi":"10.4103/ijc.ijc_223_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_223_24","url":null,"abstract":"<p>This meta-analysis aims to comprehensively evaluate the efficacy and safety of T-DM1 in treating HER2-positive breast cancer, providing insights for clinical practice. We conducted a literature search in PubMed, Cochrane Library, and Embase databases up to September 2023, collecting randomized controlled trials and cohort studies on T-DM1 for HER2-positive breast cancer. Out of 316 initially retrieved articles, 12 studies meeting the quality and inclusion criteria were included after a rigorous screening process. We used RevMan 5.3 software for the meta-analysis, employing fixed or random-effect models. Odds ratios (RRs) and 95% confidence intervals (CIs) were calculated as effect size measures. We conducted sensitivity analyses and assessed publication bias to ensure the results’ stability and reliability. In seven studies, T-DM1 treatment significantly prolonged OS in patients with HER2-positive breast cancer [hazard ratio (HR) = 0.70, 95% CI: 0.64–0.77, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> &lt; 0.01], and the effect was especially pronounced in patients with advanced disease (HR = 0.64, 95% CI: 0.54–0.76, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> &lt; 0.001). Analysis of pCR rates did not show a significant difference (OR = 0.91, 95% CI: 0.48–1.73, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> = 0.77). In five studies, ORR improved, but the difference between the two groups was not significant (OR = 1.16, 95% CI: 0.66–2.05, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> = 0.61). Analysis of progression-free survival (PFS) showed a significant improvement in the experimental group relative to the control group (HR = 0.69, 95% CI: 0.57–0.84, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> = 0.0003). Regarding the incidence of total adverse events, no significant difference was seen between the two groups (OR = 2.16, 95% CI: 0.98–4.79, <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> = 0.06), but for specific adverse events, such as leukopenia and neutropenia, the T-DM1 group demonstrated a significant reduction relative to the other treatment regimens. The results underscore the potential of T-DM1 in enhancing survival among patients with advanced HER2-positive breast cancer, yet they also highlight variability in effectiveness concerning pCR rate and ORR. The findings on adverse effects underscore the necessity of a balanced consideration of T-DM1’s risks and benefits. Future research should focus on a more detailed examination of responses in varied patient populations, long-term outcomes, and a thorough economic evaluation of T-DM1, along with an exploration into treatment resistance. This will provide a more nuanced understanding of T-DM1’s role in the treatment landscape of HER2-positive breast cancer.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"45 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140828712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}